104 related articles for article (PubMed ID: 3293438)
1. Use of differentiation-inducing agents in the myelodysplastic syndrome and acute non-lymphocytic leukemia.
Hoffman SJ; Robinson WA
Am J Hematol; 1988 Jun; 28(2):124-7. PubMed ID: 3293438
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome.
Greenberg BR; Durie BG; Barnett TC; Meyskens FL
Cancer Treat Rep; 1985 Dec; 69(12):1369-74. PubMed ID: 3865701
[TBL] [Abstract][Full Text] [Related]
3. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.
Cheson BD; Jasperse DM; Simon R; Friedman MA
J Clin Oncol; 1986 Dec; 4(12):1857-64. PubMed ID: 3537219
[TBL] [Abstract][Full Text] [Related]
4. 13-cis-Retinoic acid treatment in patients with myelodysplastic syndrome.
Leoni F; Ciolli S; Longo G; Messori A; Ferrini PR
Acta Haematol; 1988; 80(1):8-12. PubMed ID: 3135696
[TBL] [Abstract][Full Text] [Related]
5. Combination of low-dose cytarabine and 13-cis retinoic acid in the treatment of myelodysplastic syndromes.
Ho AD; Martin H; Knauf W; Reichardt P; Trümper L; Hunstein W
Leuk Res; 1987; 11(11):1041-4. PubMed ID: 3320577
[TBL] [Abstract][Full Text] [Related]
6. Differentiating agents in the treatment of leukemia and myelodysplastic syndromes.
Degos L
Leuk Res; 1990; 14(8):731-3. PubMed ID: 2201824
[TBL] [Abstract][Full Text] [Related]
7. 13-cis retinoic acid treatment for myelodysplastic syndromes.
Picozzi VJ; Swanson GF; Morgan R; Hecht F; Greenberg PL
J Clin Oncol; 1986 Apr; 4(4):589-95. PubMed ID: 3514807
[TBL] [Abstract][Full Text] [Related]
8. Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study.
Hofmann WK; Kell WJ; Fenaux P; Castaigne S; Ganser A; Chomienne C; Burnett R; Kowal C; Hoelzer D; Burnett AK
Leukemia; 2000 Sep; 14(9):1583-8. PubMed ID: 10995004
[TBL] [Abstract][Full Text] [Related]
9. Differentiation therapy of myelodysplastic syndromes with retinoic acid.
Ohno R
Leuk Lymphoma; 1994 Aug; 14(5-6):401-9. PubMed ID: 7812199
[TBL] [Abstract][Full Text] [Related]
10. Differentiating agents in the treatment of leukemia.
Degos L
Leuk Res; 1990; 14(8):717-9. PubMed ID: 2201823
[TBL] [Abstract][Full Text] [Related]
11. [Effect of treatment with 13-cis-retinoic acid and ara-C on the hematopoietic stem cells of patients with myelodysplastic syndromes].
García Marco J; Miguel Sosa A; García Conde J; Miguel García A; Arbona C; Escrig V; Benet I; Navarro I; Ruiz A; Carbonell F
Sangre (Barc); 1994 Aug; 39(4):241-4. PubMed ID: 7985051
[TBL] [Abstract][Full Text] [Related]
12. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.
Giagounidis AA; Haase S; Germing U; Schlegelberger B; Wilkens L; Büsche G; Kreipe HH; Wysk J; Grips KH; Grabenhorst U; Rothmann F; Lübbert M; Ganser A; Aivado M; Heinsch M; Aul C
Ann Hematol; 2005 Jun; 84(6):389-94. PubMed ID: 15785949
[TBL] [Abstract][Full Text] [Related]
13. Leukemia cutis. Analysis of 50 biopsy-proven cases with an emphasis on occurrence in myelodysplastic syndromes.
Longacre TA; Smoller BR
Am J Clin Pathol; 1993 Sep; 100(3):276-84. PubMed ID: 8379536
[TBL] [Abstract][Full Text] [Related]
14. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
[TBL] [Abstract][Full Text] [Related]
15. All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome.
Kurzrock R; Estey E; Talpaz M
J Clin Oncol; 1993 Aug; 11(8):1489-95. PubMed ID: 8336187
[TBL] [Abstract][Full Text] [Related]
16. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Pilatrino C; Cilloni D; Messa E; Morotti A; Giugliano E; Pautasso M; Familiari U; Cappia S; Pelicci PG; Lo Coco F; Saglio G; Guerrasio A
Cancer; 2005 Jul; 104(1):101-9. PubMed ID: 15895376
[TBL] [Abstract][Full Text] [Related]
17. Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome.
Clark RE; Jacobs A; Lush CJ; Smith SA
Lancet; 1987 Apr; 1(8536):763-5. PubMed ID: 2882180
[TBL] [Abstract][Full Text] [Related]
18. The basis for treatment of myelodysplastic syndrome and acute nonlymphoblastic leukemia with biologic agents.
Elias L
Leukemia; 1988 Jun; 2(6):400-2. PubMed ID: 2453761
[TBL] [Abstract][Full Text] [Related]
19. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.
Hu XM; Yuan B; Tanaka S; Song MM; Onda K; Tohyama K; Zhou AX; Toyoda H; Hirano T
Hematology; 2014 Sep; 19(6):352-60. PubMed ID: 24192507
[TBL] [Abstract][Full Text] [Related]
20. [The clinical effect of low-dose Ara-C in patients with refractory acute nonlymphocytic leukemia and myelodysplastic syndrome].
Yoshida M; Tsunoda S; Akutsu M; Furukawa Y; Takeda K; Akashi M; Komatsu N; Muroi K; Ikeda K; Ohsaka A
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1057-62. PubMed ID: 3566302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
